[Pharmacology of niacin or nicotinic acid].
Niacin or nicotinic acid is a soluble vitamin with hypolipidemic properties. Niacin reduces triglycerides (20 50%), LDL-c (5-25%), and raises HDL-c (15-35%). The Coronary Drug Project study showed that the use of niacin was associated with reduction on coronary events and total mortality, and more recently it has been demonstrated that niacin combined with other hypolipidemic drugs can attenuate the progression of coronary atherosclerosis. Niacin appears to reduce the mobilization of free fatty acids from the adipocytes, acting on specific receptors, diminishing the liver formation of triglyceride-rich lipoproteins. There are two forms of niacin, one of rapid absorption (crystalline), more commonly associated with flushing, and another of extended release, recently reported to be better tolerated. The use of niacin can be associated with dyspepsia, increased plasma levels of liver enzymes and also with a modest elevation in glucose and uric acid plasma levels, at least using the extended-release preparation up to 2 g/d.
Santos
Raul D
RD
Unidade Clínica de Dislipidemias, InCor-HCFMUSP.
D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000378:metabolism; D050171:Dyslipidemias / Q000188:drug therapy; D005483:Flushing / Q000139:chemically induced; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000378:metabolism*; D009525:Niacin / Q000009:adverse effects / Q000378:metabolism*
D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D009525:Niacin